8-KLeadership ChangesExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Executive Changes (Jul 15, 2020)

Filed July 15, 2020For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) announced on July 15, 2020, a significant addition to its Board of Directors. Paul A. LaViolette has been appointed to the Board, effective July 13, 2020, and will also serve on the Compensation and Governance Committee. This appointment is a key development for the company's governance structure, bringing potentially new perspectives to its strategic and compensation decisions. Mr. LaViolette's appointment appears routine, with no disclosed arrangements with other parties or material interests in company transactions requiring specific disclosure. He will be compensated according to the standard director compensation policy, as outlined in the company's prior filings, and will receive the standard indemnification agreement. Investors should note this as a governance update that could influence future board oversight and strategy.

Key Highlights

  • 1Appointment of Paul A. LaViolette to the Board of Directors, effective July 13, 2020.
  • 2Mr. LaViolette will also serve as a member of the Compensation and Governance Committee.
  • 3No disclosed arrangements or understandings between Mr. LaViolette and any other persons for his selection.
  • 4Mr. LaViolette has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
  • 5Director will receive standard compensation for non-employee directors.
  • 6Company will enter into its standard form of indemnification agreement with Mr. LaViolette.
  • 7Announcement accompanied by a press release filed as Exhibit 99.1.

Frequently Asked Questions

Paul A. LaViolette has been appointed to the Edwards Lifesciences Board of Directors and will serve on the Compensation and Governance Committee. The filing does not provide specific details on his background or the strategic rationale beyond standard appointment procedures, but it indicates a strengthening of the board's governance and compensation oversight.

The direct financial impact is limited to Mr. LaViolette's compensation as a director, which will follow the company's standard policy for non-employee directors. This is a governance-related appointment rather than a transaction with immediate financial implications.

According to the filing, there are no disclosed arrangements or understandings with other individuals regarding his selection, nor does Mr. LaViolette have any material interest in transactions requiring specific disclosure under Regulation S-K. This suggests a standard, arm's-length appointment.

Mr. LaViolette's compensation will be in line with the company's 'Director Compensation' as detailed in the 2020 Proxy Statement filed on March 25, 2020. The standard form of indemnification agreement is available as Exhibit 10.20 to the Company's 2011 Form 10-K.